Tomomi Furihata
Overview
Explore the profile of Tomomi Furihata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
92
Citations
850
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Caratis F, Karaszewski B, Klejbor I, Furihata T, Rutkowska A
PLoS One
. 2025 Feb;
20(2):e0318822.
PMID: 39999050
The endogenous ligand for the EBI2 receptor, oxysterol 7α,25OHC, crucial for immune responses, is finely regulated by CH25H, CYP7B1 and HSD3B7 enzymes. Lymphoid stromal cells and follicular dendritic cells within...
2.
Nakayama-Kitamura K, Shigemoto-Mogami Y, Piantino M, Naka Y, Yamada A, Kitano S, et al.
Biomedicines
. 2024 Nov;
12(11).
PMID: 39595066
Background: The blood-brain barrier (BBB) strictly regulates the penetration of substances into the brain, which, although important for maintaining brain homeostasis, may delay drug development because of the difficulties in...
3.
Yamagata A, Adachi R, Yokokawa A, Furihata T, Shibasaki H
Drug Metab Pharmacokinet
. 2023 Dec;
54:100541.
PMID: 38150944
We developed a method for quantifying fluticasone propionate (FP) using general-purpose liquid chromatography-tandem mass spectrometry equipment to measure the plasma concentration of FP for the pharmacokinetic study of FP following...
4.
Plasma 6β-hydroxycortisol to cortisol ratio as a less invasive cytochrome P450 3A phenotyping method
Hirano R, Yokokawa A, Furihata T, Shibasaki H
Br J Clin Pharmacol
. 2023 Dec;
90(4):1016-1026.
PMID: 38102865
Aim: A less invasive evaluation method of cytochrome P450 3A (CYP3A) activity provides an important tool for personalized medicine. We aimed to clarify the usefulness of the plasma 6β-hydroxycortisol to...
5.
Jonnalagadda D, Kihara Y, Groves A, Ray M, Saha A, Ellington C, et al.
Cell Rep
. 2023 Dec;
42(12):113545.
PMID: 38064339
Vitamin B (B) deficiency causes neurological manifestations resembling multiple sclerosis (MS); however, a molecular explanation for the similarity is unknown. FTY720 (fingolimod) is a sphingosine 1-phosphate (S1P) receptor modulator and...
6.
Zhang H, Kang D, Piantino M, Tominaga D, Fujimura T, Nakatani N, et al.
Biosensors (Basel)
. 2023 Aug;
13(8).
PMID: 37622905
The blood-brain barrier (BBB) is a selective barrier that controls the transport between the blood and neural tissue features and maintains brain homeostasis to protect the central nervous system (CNS)....
7.
Shang Y, Piantino M, Zeng J, Louis F, Xie Z, Furihata T, et al.
Mater Today Bio
. 2023 Aug;
21:100714.
PMID: 37545563
The blood-brain barrier (BBB) is a type of capillary network characterized by a highly selective barrier, which restricts the transport of substances between the blood and nervous system. Numerous models...
8.
Shima Y, Sasagawa S, Ota N, Oyama R, Tanaka M, Kubota-Sakashita M, et al.
Sci Transl Med
. 2023 Jun;
15(700):eabq7721.
PMID: 37315111
Intracranial aneurysms (IAs) are a high-risk factor for life-threatening subarachnoid hemorrhage. Their etiology, however, remains mostly unknown at present. We conducted screening for sporadic somatic mutations in 65 IA tissues...
9.
Wongwanakul R, Aueviriyavit S, Furihata T, Gonil P, Sajomsang W, Maniratanachote R, et al.
Sci Rep
. 2023 May;
13(1):7904.
PMID: 37193745
Potential use of a quaternized chitosan (MW 600 kDa) with 65% of 3-chloro-2-hydroxypropyltrimethylammonium (600-HPTChC) as an absorptive enhancer was investigated in Caco-2 monolayers. 600-HPTChC (0.005% w/v) quickly reduced transepithelial electrical...
10.
Ohki S, Ogawa S, Takano H, Shimazaki H, Fukae M, Furihata T, et al.
Biol Pharm Bull
. 2023 Apr;
46(5):736-740.
PMID: 37121701
The method of administering caffeine as a probe to evaluate the phenotypic activity of the CYP1A2, has not yet been applied clinically. In contrast, if endogenous melatonin (MEL) metabolism can...